Bill > SB1848

This bill expands the ability of certain healthcare providers to administer buprenorphine products, a medication used to treat opioid use disorder, by allowing them to directly administer buprenorphine alone or without naloxone, which is an opioid overdose reversal drug. Specifically, it amends existing law to permit healthcare providers, acting within their professional scope and under a physician's order, to administer these buprenorphine products for substance use disorder treatment, with the caveat that the medication cannot be dispensed for self-administration away from the dispensing location. Furthermore, the bill modifies restrictions on prescribing buprenorphine mono products (buprenorphine without naloxone) by clarifying that prescribing such a product to a nursing mother or prescribing an injectable mono product does not prevent other healthcare providers from prescribing buprenorphine without naloxone for opioid use disorder treatment.